The results of the long-term, open-label extension (OLE) of a randomized, double-blind, placebo-controlled study of cenobamate (C013) have been…
• Through this acquisition, Angelini Pharma will be a major player in the market of companies focused on the treatment of central nervous system…
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping…
Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million…
Zug, Switzerland, 17 August 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…
PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme Milestone further…
Zug, Switzerland, 1 June 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…
Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug, Switzerland, 26 May 2020 –…
28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1 In…
Arvelle Therapeutics has exclusive rights to develop and commercialize cenobamate in Europe Zug, Switzerland, 12 May 2020 – Arvelle…
